Device and method for monitoring aqueous flow within the eye

• US 6,939,298 B2
• Filed: 02/28/2003
• Issued: 09/06/2005
• Est. Priority Date: 02/28/2002
• Status: Expired due to Fees

• Current Assignee: Glaukos Corporation
• Original Assignee: GMP Vision Solutions, Inc.
• Inventors: Lynch, Mary G., Brown, Reay
• Primary Examiner(s): Winakur, Eric F.
• Assistant Examiner(s): KREMER, MATTHEW J
• Application Number:
  US10/376,793
• Publication Number:
  US 20030232015A1
• Time in Patent Office: 921 Days
• Field of Search: 600309-310, 600/318, 600/321, 600/398
• US Class Current: 600/309
• CPC Class Codes: A61B 3/101 for examining the tear film

Abstract

The present invention provides a device and method for monitoring the flow of aqueous humor within the eye. The invention provides that the aqueous flow rate and/or pattern within the anatomical structures of the eye can be determined by monitoring a traceable component. Such determination provides diagnostic indications of the degree and location of ocular disease associated with aqueous outflow, such as glaucoma, and can further provide post-treatment indications of effectiveness.

Claims

1. A method of determining a pattern and extent of aqueous outflow in the eye, comprising monitoring the flow of aqueous humor in an anatomical structure of the eye associated with aqueous humor flow, wherein monitoring the flow of aqueous humor comprises the steps of:

a) measuring the flow of aqueous humor at a first anatomical structure of the eye associated with aqueous humor flow; and

b) comparing the flow of aqueous humor at the first anatomical structure to the flow of aqueous humor at a second anatomical structure of the eye associated with aqueous humor flow

to thereby monitor the flow of aqueous humor wherein the flow of aqueous humor is determined relative to observation of a monitored flow of a traceable component.

2. The method of claim 1, wherein the traceable component is administered topically.

3. The method of claim 1, wherein the traceable component is administered directly into the anterior chamber.

4. The method of claim 1, wherein the traceable component is administered directly into an anatomical structure of the eye associated with aqueous humor flow, selected from the group comprising an anterior chamber, a trabecular meshwork, a Schlemm'"'"'s canal, a collecting channel, an aqueous vein, and an episcleral vein.

5. The method of claim 1, wherein the traceable component is selected from the group consisting of a colored dye, a radiopaque dye, a fluorescing compound, a radioisotope, and a gaseous precursor filled microsphere.

6. The method of claim 1, wherein monitoring the flow of aqueous humor is performed without the administration of an exogenous traceable component.

7. The method of claim 1, wherein the monitoring step identifies an aqueous outflow obstruction in an eye of a patient with glaucoma.

8. The method of claim 1, wherein the monitoring step identifies a response to therapeutic intervention in an eye of a patient with glaucoma.

9. A method of determining a pattern and extent of aqueous outflow in the eye, comprising monitoring the flow of aqueous humor in an anatomical structure of the eye associated with aqueous humor flow, wherein monitoring the flow of aqueous humor comprises the steps of:

a) measuring the flow of aqueous humor at a first location in an anatomical structure of the eye associated with aqueous humor flow; and

b) comparing the flow of aqueous humor at the first location in an anatomical structure of the eye to the flow of aqueous humor at a second location in the same anatomical structure of the eye

wherein the flow of aqueous humor is determined relative to observation of a monitored flow of a traceable component.

10. The method of claim 9, wherein the traceable component is administered topically.

11. The method of claim 9, wherein the traceable component is administered directly into the anterior chamber.

12. The method of claim 9, wherein the traceable component is administered directly into an anatomical structure of the eye associated with aqueous humor flow, selected from the group comprising an anterior chamber, a trabecular meshwork, a Schlemm'"'"'s canal, a collecting channel, an aqueous vein, and an episcleral vein.

13. The method of claim 9, wherein the traceable component is selected from the group consisting of a colored dye, a radiopaque dye, a fluorescing compound, a radioisotope, and a gaseous precursor filled microsphere.

14. The method of claim 9, wherein monitoring the flow of aqueous humor is performed without the administration of an exogenous traceable component.

15. The method of claim 9, wherein the monitoring step identifies an aqueous outflow obstruction in an eye of a patient with glaucoma.

16. The method of claim 9, wherein the monitoring step identifies a response to therapeutic intervention in an eye of a patient with glaucoma.

17. A method of determining a pattern and extent of aqueous outflow in the eye, comprising monitoring the flow of aqueous humor in an anatomical structure of the eye associated with aqueous humor flow, wherein monitoring the flow of aqueous humor comprises the steps of:

a) measuring the flow of aqueous humor at a first location in an anatomical structure of the eye associated with aqueous humor flow; and

b) comparing the flow of aqueous humor at the first location to the flow of aqueous humor at the first location after a period of time,

wherein the flow of aqueous humor is determined relative to observation of a monitored flow of a traceable component, and wherein the traceable component is administered directly into the anterior chamber.

18. The method of claim 17, wherein the traceable component is selected from the group consisting of a colored dye, a radiopaque dye, a fluorescing compound, a radioisotope, and a gaseous precursor filled microsphere.

19. The method of claim 17, wherein monitoring the flow of aqueous humor is performed without the administration of an exogenous traceable component.

20. The method of claim 17, wherein the monitoring step identifies an aqueous outflow obstruction in an eye of a patient with glaucoma.

21. The method of claim 17, wherein the monitoring step identifies a response to therapeutic intervention in an eye of a patient with glaucoma.